Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03835884 · ClinicalTrials.gov registry record · Phase 1
A Study Assessing AR-13503 Implant in Subjects With nAMD or DME
A Phase 1 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03835884 is a Phase 1 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT03835884, a Phase 1 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects with Neovascular Age-Related Macular Degeneration (nAMD) and Subjects with Diabetic Macular Edema (DME)
Interventions
- DRUG AR-13503 Implant 10.6 Dose
- DRUG AR-13503 Implant 21.2 Dose
- DRUG AR-13503 42.4 Dose
- DRUG AR-13503 63.6 Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-06-24 |
| Est. Completion | 2022-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03835884
The ClinicalTrials.gov registry entry for NCT03835884 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which AR-13503 Implant 10.6 Dose is the first listed.
NCT03835884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03835884 about?
NCT03835884 is a clinical study titled "A Study Assessing AR-13503 Implant in Subjects With nAMD or DME". First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects with Neovascular Age-Related Macular Degeneration (nAMD) and Subjects with Diabetic Macular Edema (DME)
What is the current status of trial NCT03835884?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2019-06-24. Estimated completion is 2022-05-12.
What interventions are being tested in trial NCT03835884?
The interventions under investigation include: AR-13503 Implant 10.6 Dose (DRUG), AR-13503 Implant 21.2 Dose (DRUG), AR-13503 42.4 Dose (DRUG), AR-13503 63.6 Dose (DRUG).
Who is sponsoring clinical trial NCT03835884?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.